跳至主要内容
临床试验/NCT00688831
NCT00688831已完成1 期

A Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Ascending Intravenous Doses of AZD1305 in Helahty Male Volunteers

AstraZeneca1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
AstraZeneca
入组人数
36
试验地点
1
主要终点
Adverse events, ECG variables, vital signs, physical examination, laboratory variables, body temperature and weight

研究概览

简要总结

The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body (how it is taken up into the body, distributed around the body and disappears from the body

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy volunteers
  • BIM 19-30 kg/m2

排除标准

  • Potassium outside normal reference values
  • ECG findings outside normal range

研究组 & 干预措施

A

Experimental

AZD1305 solution for iv infusion

干预措施: AZD1305 (Drug)

B

Placebo Comparator

NaCl solution for iv infusion

干预措施: Placebo (Drug)

结局指标

主要结局

Adverse events, ECG variables, vital signs, physical examination, laboratory variables, body temperature and weight

时间窗: During the study

次要结局

  • Pharmacokinetic variables(During all dosing visits)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验